Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Immuron Limited - Product Pipeline Review - 2012

958.45

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£958.45

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Company Profile

Country

Global

Published

31 October 2012

Number of Pages

56

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

Global Markets Direct

File Format

PDF

10% off Global Markets Direct & CBR Pharma Insights Reports in December 10% off Global Markets Direct & CBR Pharma Insights Reports in December

Discounted price shows in basket.

Immuron Limited – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Immuron Limited - Product Pipeline Review - 2012" provides data on the Immuron Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from our proprietary databases, Immuron Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Immuron Limited and industry-specific third party sources, put together by our team.

Scope

- Immuron Limited - Brief Immuron Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immuron Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immuron Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immuron Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Immuron Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immuron Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immuron Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immuron Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immuron Limited and identify potential opportunities in those areas.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£958.45

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

December Discounted Prices: Contact us to ask about our special discounts available in December

For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.

Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.

Find all the research at the best prices. Great promotions being offered during December!

We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.

Accessibility
Close

Contrast settings

Text size settings